サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：計算生物学の世界市場：2023-2030年
市場調査レポート
商品コード
1380467

計算生物学の世界市場：2023-2030年

Global Computational Biology Market 2023-2030
出版日: | 発行: Orion Market Research | ページ情報: 英文 194 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
計算生物学の世界市場：2023-2030年
出版日: 2023年10月02日
発行: Orion Market Research
ページ情報: 英文 194 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の計算生物学市場は、予測期間中にCAGR 15.8%の大幅な成長が見込まれています。計算生物学とは、データ解析、数学的モデリング、計算シミュレーションを用いて、生物学的システムや関係を理解することです。遺伝子配列、細胞集団、タンパク質サンプルのような大規模な生物学的データの集合を計算手法で解析する学際的な分野です。がん、心臓病、糖尿病などの慢性疾患は、世界の健康問題です。計算生物学は、慢性疾患の新薬や治療法の開発、またこれらの疾患の診断や管理の改善に利用されています。これが市場成長の主な促進要因の一つです。計算生物学ツールは、ゲノム、トランスクリプトーム、プロテオミクスの大規模データセットを解析し、慢性疾患の発症や進行に関与する新たな遺伝子やタンパク質を同定するために利用できます。このような新たな創薬標的が同定されれば、研究者はこれらの分子を標的とする新薬の開発に着手することができます。計算生物学的ツールは、より効果的で副作用の少ない新薬の設計に利用できます。例えば、計算生物学ツールを使って、薬物分子と標的タンパク質との相互作用をシミュレートし、最も効果的な薬物構造を特定することができます。計算生物学ツールは、臨床試験前に薬剤の毒性や有効性を予測するのにも利用できます。これにより、医薬品開発プロセスにおける時間と費用の節約につながります。計算生物学的ツールは、新たな診断検査の開発や、慢性疾患患者のための個別化治療計画の立案にも利用できます。例えば、計算生物学ツールを使って患者の遺伝子プロファイルを解析し、その患者に最も効果的で安全な治療法を特定することができます。

慢性疾患の新薬開発に計算生物学が利用されている例として、がん標的療法の開発があります。標的がん治療薬とは、がん細胞の増殖と生存に関与する特定の分子を標的とする薬剤です。計算生物学のツールは、がんの新たな創薬標的の同定、がんの新たな標的療法の設計、臨床試験におけるがんの標的療法の有効性の予測に利用されています。慢性疾患の診断と管理を改善するために計算生物学が利用されているもう一つの例は、糖尿病に対する個別化医療アプローチの開発です。糖尿病は、血糖値を調節するホルモンであるインスリンの産生能力や使用能力に影響を及ぼす慢性疾患です。計算生物学的ツールは、糖尿病患者の遺伝子プロファイルを解析し、特定の患者にとって最も効果的で安全な治療法を特定するために使用されています。

セグメント別の展望

計算生物学市場では、最終用途部門が大きなシェアを占める

世界の計算生物学市場では、製薬・バイオテクノロジー企業が最終用途別で大きなシェアを占めています。これは、製薬・バイオテクノロジー企業が新薬や治療法開発の最前線に立ち、その過程で計算生物学がますます重要な役割を果たしているためです。製薬企業やバイオテクノロジー企業が計算生物学をどのように活用しているかの一例として、創薬プロセスが挙げられます。従来、創薬は、治療効果が期待できる数種類の化合物を見出すために、何百万もの化合物をスクリーニングするという、長い時間と費用のかかるプロセスでした。しかし、計算生物学ツールを使えば、有望な創薬標的を特定し、より効果が期待できる新薬を設計することができるため、このプロセスを加速することができます。

地域別の展望

世界の計算生物学市場は、北米（米国とカナダ）、欧州（イタリア、スペイン、ドイツ、フランス、その他）、アジア太平洋（インド、中国、日本、韓国、その他）、世界のその他の地域（中東とアフリカ、ラテンアメリカ）の地域別にさらに細分化されています。このうち、北米が大きな市場シェアを占めている理由は数多くあるが、そのひとつは、大手製薬会社やバイオテクノロジー企業、そして主要な学術機関が存在することです。

欧州は世界市場で安定した成長が見込まれる

欧州地域は世界市場で一貫した成長率を示しています。欧州における計算生物学市場の成長は、創薬・市場開拓への投資の増加や個別化医療の導入拡大が牽引しています。欧州は製薬企業やバイオテクノロジー企業の主要拠点であり、これらの企業は創薬や薬剤開発に多額の投資を行っています。計算生物学はこのプロセスでますます重要な役割を果たすようになっており、研究者は新薬ターゲットの同定、新薬の設計、薬剤の毒性と効力の予測に役立てています。個別化医療は、個々の患者の遺伝子プロファイルに合わせて治療を行う、ヘルスケアへの新しいアプローチです。計算生物学ツールは、患者の遺伝子プロファイルを解析し、その特定の患者にとって最も効果的で安全な治療法を特定するために使用できるため、個別化医療には不可欠です。

目次

第1章 レポート概要

  • 業界の現状分析と成長ポテンシャルの展望
  • 調査方法とツール
  • 市場内訳
    • セグメント別
    • 地域別

第2章 市場概要と洞察

  • 調査範囲
  • アナリストの洞察と現在の市場動向
    • 主な調査結果
    • 推奨事項
    • 結論

第3章 競合情勢

  • 主要企業分析
  • Dassault Systemes
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Illumina, Inc.
    • 会社概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • QIAGEN GmbH
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Schrodinger, LLC.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • Thermo Fisher Scientific Inc.
    • 概要
    • 財務分析
    • SWOT分析
    • 最近の動向
  • 主要戦略分析

第4章 市場セグメンテーション

  • 計算生物学の世界市場：用途別
    • 創薬・医薬品開発
    • 臨床試験
    • 人体シミュレーションソフトウェア
    • 前臨床医薬品開発
    • その他（細胞・生体シミュレーション）
  • 計算生物学の世界市場：サービス別
    • ソフトウェアプラットフォーム
    • インフラとハードウェア
    • コンサルティングサービス
  • 計算生物学の世界市場：最終用途別
    • 学術・研究機関
    • 製薬・バイオテクノロジー企業
    • 臨床診断企業

第5章 地域別分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • 韓国
    • その他アジア太平洋地域
  • 世界のその他の地域

第6章 企業プロファイル

  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.
  • Certara, Inc.
  • Chemical Computing Group ULC（"CCG"）
  • Compugen
  • DNAnexus, Inc.
  • DNASTAR
  • Genedata
  • InSilico Medicine
  • Intelisys, Inc.
  • Nimbus Therapeutics
  • Oxford Nanopore Technologies plc
  • PacBio.
  • PerkinElmer U.S. LLC.
  • PhenX
  • Simulations Plus
  • Yokogawa Insilico Biotechnology GmbH
図表

LIST OF TABLES

  • 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2030 ($ MILLION)
  • 2. GLOBAL COMPUTATIONAL BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION,2023-2030 ($ MILLION)
  • 3. GLOBAL COMPUTATIONAL BIOLOGY IN CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 4. GLOBAL COMPUTATIONAL BIOLOGY IN HUMAN BODY SIMULATION SOFTWARE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 5. GLOBAL COMPUTATIONAL BIOLOGY IN PRECLINICAL DRUG DEVELOPMENT MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 6. GLOBAL COMPUTATIONAL BIOLOGY IN OTHERS (CELLULAR AND BIOLOGICAL SIMULATION) MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 7. GLOBAL COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY SERVICE, 2023-2030 ($ MILLION)
  • 8. GLOBAL COMPUTATIONAL BIOLOGY BY SOFTWARE PLATFORMS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 9. GLOBAL COMPUTATIONAL BIOLOGY BY INFRASTRUCTURE AND HARDWARE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 10. GLOBAL COMPUTATIONAL BIOLOGY BY CONSULTING SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 11. GLOBAL COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY END-USE, 2023-2030 ($ MILLION)
  • 12. GLOBAL COMPUTATIONAL BIOLOGY FOR ACADEMIA AND RESEARCH MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 13. GLOBAL COMPUTATIONAL BIOLOGY FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 14. GLOBAL COMPUTATIONAL BIOLOGY FOR CLINICAL DIAGNOSTICS COMPANIES MARKET AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 15. GLOBAL COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2030 ($ MILLION)
  • 16. NORTH AMERICAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2030 ($ MILLION)
  • 17. NORTH AMERICAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2030 ($ MILLION)
  • 18. NORTH AMERICAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY SERVICE, 2023-2030 ($ MILLION)
  • 19. NORTH AMERICAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY END-USE, 2023-2030 ($ MILLION)
  • 20. EUROPEAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2030 ($ MILLION)
  • 21. EUROPEAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2030 ($ MILLION)
  • 22. EUROPEAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY SERVICE, 2023-2030 ($ MILLION)
  • 23. EUROPEAN COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY END-USE, 2023-2030 ($ MILLION)
  • 24. ASIA- PACIFIC COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2030 ($ MILLION)
  • 25. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2030 ($ MILLION)
  • 26. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY SERVICE, 2023-2030 ($ MILLION)
  • 27. ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY END-USE, 2023-2030 ($ MILLION)
  • 28. REST OF THE WORLD COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2030 ($ MILLION)
  • 29. REST OF THE WORLD COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2030 ($ MILLION)
  • 30. REST OF THE WORLD COMPUTATIONAL BIOLOGY MARKET RESEARCH AND END-USE BY SERVICE, 2023-2030 ($ MILLION)
  • 31. REST OF THE WORLD COMPUTATIONAL BIOLOGY MARKET RESEARCH AND ANALYSIS BY END-USE, 2023-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL COMPUTATIONAL BIOLOGY MARKET SHARE BY APPLICATION, 2023 VS 2030 (%)
  • 2. GLOBAL COMPUTATIONAL BIOLOGY IN DRUG DISCOVERY AND DEVELOPMENT MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 3. GLOBAL COMPUTATIONAL BIOLOGY IN CLINICAL TRIALS MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 4. GLOBAL COMPUTATIONAL BIOLOGY IN HUMAN BODY SIMULATION SOFTWARE MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 5. GLOBAL COMPUTATIONAL BIOLOGY IN PRECLINICAL DRUG DEVELOPMENT MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 6. GLOBAL COMPUTATIONAL BIOLOGY IN OTHERS (CELLULAR AND BIOLOGICAL SIMULATION) MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 7. GLOBAL COMPUTATIONAL BIOLOGY MARKET SHARE BY SERVICE, 2023 VS 2030 ($ MILLION)
  • 8. GLOBAL COMPUTATIONAL BIOLOGY BY SOFTWARE PLATFORMS MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 9. GLOBAL COMPUTATIONAL BIOLOGY BY INFRASTRUCTURE AND HARDWARE MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 10. GLOBAL COMPUTATIONAL BIOLOGY BY CONSULTING SERVICES MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 11. GLOBAL COMPUTATIONAL BIOLOGY MARKET SHARE ANALYSIS BY END-USE, 2023-2030 ($ MILLION)
  • 12. GLOBAL COMPUTATIONAL BIOLOGY FOR ACADEMIA AND RESEARCH MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 13. GLOBAL COMPUTATIONAL BIOLOGY FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES MARKET SHARE BY REGION, 2023 VS. 2030 (%)
  • 14. GLOBAL COMPUTATIONAL BIOLOGY FOR CLINICAL DIAGNOSTICS COMPANIES MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 15. GLOBAL COMPUTATIONAL BIOLOGY MARKET SHARE BY REGION, 2023 VS 2030 (%)
  • 16. US COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 17. CANADA COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 18. UK COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 19. FRANCE COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 20. GERMANY COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 21. ITALY COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 22. SPAIN COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 23. REST OF EUROPE COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 24. INDIA COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 25. CHINA COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 26. JAPAN COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 27. SOUTH KOREA COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 28. REST OF ASIA-PACIFIC COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
  • 29. REST OF THE WORLD COMPUTATIONAL BIOLOGY MARKET SIZE, 2023-2030 ($ MILLION)
目次
Product Code: OMR2027853

Title: Global Computational Biology Market Size, Share & Trends Analysis Report Market by Application (Drug discovery and development, Clinical trials, Human body simulation software, Preclinical drug development, and Others (Cellular and biological simulation)), by Service (Software platforms Infrastructure and hardware, Consulting services), End-use(Academia and research, Pharmaceutical and biotechnology companies, Clinical diagnostics companies)Forecast Period (2023-2030).

The global Computational biology market is anticipated to grow at a considerable CAGR of 15.8% during the forecast period. Computational biology is the use of data analysis, mathematical modeling, and computational simulations to understand biological systems and relationships. It's an interdisciplinary field that uses computational methods to analyze large collections of biological data, such as genetic sequences, cell populations, or protein samples. Chronic diseases, such as cancer, heart disease, and diabetes, are a major global health problem. Computational biology is being used to develop new drugs and treatments for chronic diseases, as well as to improve the diagnosis and management of these diseases. This is one of the key drivers for the market growth. Computational biology tools can be used to analyze large datasets of genomic, transcriptomic, and proteomic data to identify new genes and proteins that play a role in the development and progression of chronic diseases. Once these new drug targets have been identified, researchers can begin to develop new drugs that target these molecules. Computational biology tools can be used to design new drugs that are more effective and have fewer side effects. For example, computational biology tools can be used to simulate the interaction between a drug molecule and its target protein to identify the most effective drug structure. Computational biology tools can be used to predict the toxicity and efficacy of drugs before they are tested in clinical trials. This can help to save time and money in the drug development process. Computational biology tools can be used to develop new diagnostic tests and to develop personalized treatment plans for patients with chronic diseases. For example, computational biology tools can be used to analyze the patient's genetic profile to identify the most effective and safest treatments for that particular patient.

One example of how computational biology is being used to develop new drugs for chronic diseases is the development of targeted cancer therapies. Targeted cancer therapies are drugs that target specific molecules that are involved in the growth and survival of cancer cells. Computational biology tools are being used to identify new drug targets for cancer, to design new targeted cancer therapies, and to predict the efficacy of targeted cancer therapies in clinical trials. Another example of how computational biology is being used to improve the diagnosis and management of chronic diseases is the development of personalized medicine approaches for diabetes. Diabetes is a chronic disease that affects the body's ability to produce or use insulin, a hormone that regulates blood sugar levels. Computational biology tools are being used to analyze the genetic profile of patients with diabetes to identify the most effective and safest treatments for that particular patient.

Segmental Outlook

The global Computational biology market is segmented based on application, service, and end-use. Based on the application, the market is segmented into drug discovery and development, clinical trials, human body simulation software, preclinical drug development, and others (cellular and biological simulation) and others. Based on service, the market is sub-segmented into software platforms, infrastructure, and hardware, consulting services). Based on end-use, the market is sub-segmented into academia and research, pharmaceutical and biotechnology companies, clinical diagnostics companies, and others.

The End-use Segment showed a major market share for the Computational biology market

Pharmaceutical and biotechnology companies hold the major market share in the global computational biology market by end-use. This is because pharmaceutical and biotechnology companies are at the forefront of developing new drugs and treatments for diseases, and computational biology is playing an increasingly important role in this process. One example of how pharmaceutical and biotechnology companies are using computational biology is in the drug discovery process. Traditionally, drug discovery has been a long and expensive process, involving the screening of millions of compounds to find a few that may have potential therapeutic effects. However, computational biology tools can be used to accelerate this process by helping researchers to identify promising drug targets and to design new drugs that are more likely to be effective.

Regional Outlook

The global Computational biology market is further segmented based on geography, including North America (the US and Canada), Europe (Italy, Spain, Germany, France, and others), Asia-Pacific (India, China, Japan, South Korea, and others), and the Rest of the World (the Middle East & Africa and Latin America). Among these, North America holds the major market share for many reasons, one of which is the presence of major pharmaceutical and biotechnology companies, as well as leading academic institutions.

Europe is expected to grow at a consistent pace in the global market

The European region is experiencing a consistent growth rate in the global market. The growth of the computational biology market in Europe is being driven by increasing investments in drug discovery and development, as well as the growing adoption of personalized medicine. Europe is a major hub for pharmaceutical and biotechnology companies, and these companies are investing heavily in drug discovery and development. Computational biology is playing an increasingly important role in this process, helping researchers to identify new drug targets, design new drugs, and predict the toxicity and efficacy of drugs. Personalized medicine is a new approach to healthcare that affects treatments to the individual patient's genetic profile. Computational biology tools are essential for personalized medicine, as they can be used to analyze the patient's genetic profile to identify the most effective and safest treatments for that particular patient.

Market Players Outlook

The major companies serving the global Computational biology market include: Dassault Systemes, Illumina, Inc., QIAGEN GmbH, Schrodinger, LLC., and Thermo Fisher Scientific Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies, including mergers and acquisitions, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in May 2022, global professional services firm ZS acquired a Danish informatics and systems biology company named Intomics. The 42 members of Intomics will join ZS's staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, data science, and technology expertise with a research mindset to advance the adoption of in-silico methods in drug discovery.

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global computational biology market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Dassault Systemes
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Illumina, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. QIAGEN GmbH
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Schrodinger, LLC.
    • 3.5.1. Overview
    • 3.5.2. Financial Analysis
    • 3.5.3. SWOT Analysis
    • 3.5.4. Recent Developments
  • 3.6. Thermo Fisher Scientific Inc.
    • 3.6.1. Overview
    • 3.6.2. Financial Analysis
    • 3.6.3. SWOT Analysis
    • 3.6.4. Recent Developments
  • 3.7. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Computational Biology Market by Application
    • 4.1.1. Drug discovery and development
    • 4.1.2. Clinical trials
    • 4.1.3. Human body simulation software
    • 4.1.4. Preclinical drug development
    • 4.1.5. Others (Cellular and biological simulation)
  • 4.2. Global Computational Biology Market by Service
    • 4.2.1. Software platforms
    • 4.2.2. Infrastructure and hardware
    • 4.2.3. Consulting services
  • 4.3. Global Computational Biology Market by End-use
    • 4.3.1. Academia and research
    • 4.3.2. Pharmaceutical and biotechnology companies
    • 4.3.3. Clinical diagnostics companies

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

 

6. Company Profiles

  • 6.1. Agilent Technologies, Inc.
  • 6.2. Bio-Rad Laboratories, Inc.
  • 6.3. Certara, Inc.
  • 6.4. Chemical Computing Group ULC ("CCG")
  • 6.5. Compugen
  • 6.6. DNAnexus, Inc.
  • 6.7. DNASTAR
  • 6.8. Genedata
  • 6.9. InSilico Medicine
  • 6.10. Intelisys, Inc.
  • 6.11. Nimbus Therapeutics
  • 6.12. Oxford Nanopore Technologies plc
  • 6.13. PacBio.
  • 6.14. PerkinElmer U.S. LLC.
  • 6.15. PhenX
  • 6.16. Simulations Plus
  • 6.17. Yokogawa Insilico Biotechnology GmbH